drugset / Trial / NCT04047953
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 conversion therapy for initial unresectable local progression or potential resectable metastatic gastric adenocarcinoma.
Timeline
- Start
- 2019-09-10
- Primary completion
- 2023-12-31
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 150 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 40 mg | — |
| Subject | S-1 | Small molecule | 50 mg | — |
| Subject | S-1 | Small molecule | 60 mg | — |